Shares of Tempest Therapeutics (NASDAQ:TPST) closed nearly 4,000% higher Wednesday after the company released updated data from a Phase 1/2 study of its drug TPST-1120 in the first-line treatment of advanced or metastatic hepatocellular carcinoma, a type of liver cancer.
The stock closed at $9.77 after opening at $2.13.
In conjunction with the study update, the...
$TPST WAVE ANALYSIS; SINE WAVES
SUPPORT AND RESISTANCE
Wyckoff Re-accumulation after decline
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecules that combine targeted and immune-mediated mechanisms with the potential to treat various tumors. The company's two novel clinical programs are TPST-1495 and TPST-1120,...